ArticleJACC. Basic to translational science2021
The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic Approaches.
Article in JACC. Basic to translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05925790 (Observational Study on Anti-interleukin-1 Receptor Antagonist Antibodies and Soluble Urokinase Plasminogen Activator Receptor), which is not on this map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Observational Study on Anti-interleukin-1 Receptor Antagonist Antibodies and Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Pericarditis: PERIPLO (PERicarditis: IL-1 RA Antibodies and suPAR Levels Observational) Study
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging.JACC. Cardiovascular imaging · 2024Guideline
- Efficacy and Safety of Interleukin-1 Inhibitors in the Management of Patients with Recurrent Pericarditis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Pooled it
- Efficacy and Safety of Pharmaceutically Manufactured Cannabidiol in Recurrent Pericarditis: A Phase II Clinical Trial.Journal of the American Heart Association · 2026Trial
- Single-cell RNA profiling suggests goflikicept-mediated immune modulation in idiopathic recurrent pericarditis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Targeting NLRP3 inflammasome to mitigate chemotherapy-induced cardiotoxicity: advances in selective inhibitors and natural modulators.Molecular biology reports · 2026Review
- Updates on Pathophysiology of Pericarditis to Guide Development of Therapeutics.Current cardiology reports · 2026Review
- Cofilin-1 is a redox-sensitive guard of the NLRP3 inflammasome.Nature immunology · 2026Article
- A single-cell and spatial transcriptomic atlas of human tuberculous constrictive pericardium.EBioMedicine · 2026Article
- Contemporary Assessment and Management of Effusive-Constrictive Pericarditis.Current cardiology reports · 2026Review
- AFrontiers in immunology · 2026Article
- Fundamentals of Acute Pericarditis: State of the Art.Arquivos brasileiros de cardiologia · 2026Review
- Radiation meets inflammation: NLRP3 inflammasome at the core of radiation-induced cardiac injury.Journal of translational medicine · 2025Review
- Post-Cardiac Injury Syndrome: A Paradigm Shift in Diagnosis and Management.JACC. Advances · 2025Review
- Clinical and serological characterization of acute pleuropericarditis suggests an autoinflammatory pathogenesis and highlights risk factors for recurrent attacks.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- The expanding role of the NLRP3 inflammasome from periodic fevers to therapeutic targets.Nature immunology · 2025Review
- Understanding Hemodialysis-Associated Pericarditis: Causes, Symptoms, and Management Strategies.Journal of clinical medicine · 2025Review
- A Combined Approach to the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery.Biomedicines · 2025Article
- Shared Mechanisms in Cancer and Cardiovascular Disease: S100A8/9 and the NLRP3 Inflammasome: JACC: CardioOncology State-of-the-Art Review.JACC. CardioOncology · 2025Review
- Comparative Efficacy and Safety of Colchicine and Anti-Interleukin-1 Agents in Recurrent Pericarditis: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials.Journal of the American Heart Association · 2025Review
- Genome-wide association study of myocarditis and pericarditis following COVID-19 vaccination.NPJ vaccines · 2025Article
Corrections and comments
- Commented on by
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human samples of patients with chronic pericarditis and appropriate control subjects were stained for the inflammasome components. A mouse model of pericarditis was developed through the intrapericardial injection of zymosan A. Different inflammasome blockers were tested in the mouse model. Patients with pericarditis presented an intensification of the inflammasome activation compared with control subjects. The experimental model showed the pathological features of pericarditis. Among inflammasome blockers, NLRP3 inflammasome inhibitor, anakinra, and interleukin-1 trap were found to significantly improve pericardial alterations. Colchicine partially improved the pericardial inflammation. An intense activation of the inflammasome in pericarditis was demonstrated both in humans and in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.